Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Friedlander

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Gynecologic Oncology|July 29, 2018
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trialsNicola S Meagher, Klaus Schuster, Andreas Voss, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 21, 2005
Obesity and outcomes in premenopausal and postmenopausal breast cancerSherene Loi, Roger L Milne, Michael L Friedlander, et al.
CA: a Cancer Journal for Clinicians|March 5, 2014
Chemotherapy-induced peripheral neurotoxicity: a critical analysisSusanna B Park, David Goldstein, Arun V Krishnan, et al.
Gynecologic Oncology|February 27, 2021
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancerKatrin M Sjoquist, David Espinoza, Linda Mileshkin, et al.
International Journal of Cancer|June 17, 2020
A healthy lifestyle and survival among women with ovarian cancerJessy M Hansen, Christina M Nagle, Torukiri I Ibiebele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2004
Prognosis of premenopausal breast cancer and childbirth prior to diagnosisKelly-Anne Phillips, Roger L Milne, Michael L Friedlander, et al.
Hereditary Cancer in Clinical Practice|September 4, 2009
Prostate screening uptake in Australian BRCA1 and BRCA2 carriersJoanne M McKinley, Prue C Weideman, Mark A Jenkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family RegistryKelly-Anne Phillips, Roger L Milne, Saundra Buys, et al.
Journal of Cancer Research and Clinical Oncology|January 30, 2020
Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?Viola Heinzelmann-Schwarz, André B Kind, Marcus Vetter, et al.
BMC Cancer|December 24, 2014
Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypesSusanna B Park, John B Kwok, Clement T Loy, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Gynecologic Oncology|July 29, 2018
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trialsNicola S Meagher, Klaus Schuster, Andreas Voss, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 21, 2005
Obesity and outcomes in premenopausal and postmenopausal breast cancerSherene Loi, Roger L Milne, Michael L Friedlander, et al.
CA: a Cancer Journal for Clinicians|March 5, 2014
Chemotherapy-induced peripheral neurotoxicity: a critical analysisSusanna B Park, David Goldstein, Arun V Krishnan, et al.
Gynecologic Oncology|February 27, 2021
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancerKatrin M Sjoquist, David Espinoza, Linda Mileshkin, et al.
International Journal of Cancer|June 17, 2020
A healthy lifestyle and survival among women with ovarian cancerJessy M Hansen, Christina M Nagle, Torukiri I Ibiebele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2004
Prognosis of premenopausal breast cancer and childbirth prior to diagnosisKelly-Anne Phillips, Roger L Milne, Michael L Friedlander, et al.
Hereditary Cancer in Clinical Practice|September 4, 2009
Prostate screening uptake in Australian BRCA1 and BRCA2 carriersJoanne M McKinley, Prue C Weideman, Mark A Jenkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family RegistryKelly-Anne Phillips, Roger L Milne, Saundra Buys, et al.
Journal of Cancer Research and Clinical Oncology|January 30, 2020
Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?Viola Heinzelmann-Schwarz, André B Kind, Marcus Vetter, et al.
BMC Cancer|December 24, 2014
Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypesSusanna B Park, John B Kwok, Clement T Loy, et al.
Pageof 9